Example Validation Master Plan | IVT - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Example Validation Master Plan | IVT

IVT

Validation Week
SPOTLIGHT EVENT

IVT’s 19th Annual
Validation Week

October 22-24, 2013
San Diego, California

Brochure | Register

RELATED ARTICLES

More in GMPs/Validation

Tim Fields
Example of process validation life cycle

This Validation Master Plan serves as a summary of the overall strategy for the validation of a facility. This Validation Master Plan provides an overview of the each process and describes the validation approach along with supporting validation rationale.

This VMP addresses the all activities related to equipment, utilities, processes, systems, and procedures that may impact the product quality.  Specific systems, equipment, utilities, and procedures to be qualified and processes to be validated shall be determined based on documented risk assessment.

The purpose of the validation plan is to demonstrate that the critical equipment, systems, and processes perform as designed and intended.  All validation will be conducted prospectively following written and approved protocols.  Change control and qualification of equipment and systems will be conducted in a manner consistent with a company's policies and procedures.  Specific equipment, systems, and processes to be validated will be determined based on a documented risk assessment.  

Download the example Validation Master Plan.

Download the accompanying presentation "Writing Effective Validation Protocols and Validation Master Plans," from IVT's 15th Annual Validation Week, Philadelphia, PA, October 2009.

This article was originally published for IVT - read article on IVT here: Example Validation Master Plan | IVT.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
6%
All of the above.
42%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: IVT,
Click here